menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Meeting Eye-to-Eye: A Patient-Provider Exchange on Improving Treatment in nAMD Through Sustained Delivery

close
0.50 credits
30 Minutes
Meeting Eye-to-Eye: A Patient-Provider Exchange on Improving Treatment in nAMD Through Sustained Delivery
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
Details
Presenters
Related
Comments
  • Overview

    The incidence of neovascular age-related macular degeneration (nAMD) is rising as a large segment of the US population ages. Despite recent advances in treatment, frequent injections and monitoring visits create a burden on patients that often leads to nonadherence, undertreatment, and suboptimal visual outcomes. In this unique educational activity, a patient with nAMD and 2 experts in retinal disease treatment discuss unmet needs in nAMD, strategies to reduce treatment burden using current therapies, and emerging strategies that harness either an implantable port or viral vectors to deliver anti–vascular endothelial growth factor therapy continuously to the vitreous. The desired results of this educational activity are for retina specialists and other ophthalmologists to use current evidence to support patient-centered treatment strategies for nAMD that minimize treatment burden while maximizing vision and quality of life outcomes.

  • Disclosure of Conflicts of Interest

    Disclosure Policy
    MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity.

    Faculty
    Arshad M. Khanani, MD, MA, is a consultant for Adverum, Allergan, Bausch & Lomb Incorporated, Chengdu Kanghong Pharmaceutical Group Co Ltd, D.O.R.C. Dutch Ophthalmic Research Center (International) B.V., EyePoint Pharmaceuticals, Gemini Therapeutics, Genentech, Inc, Gyroscope, Kodiak Sciences Inc, Novartis Pharmaceuticals Corporation, Opthea, Oxurion NV, Recens Medical, Inc, and Regenxbio Inc; is on the speakers bureau for Allergan, F. Hoffman-La Roche Ltd, Genentech, Inc, and Novartis Pharmaceuticals Corporation; and is a contracted researcher for Adverum, Allergan, Chengdu Kanghong Pharmaceutical Group Co Ltd, Gemini Therapeutics, Genentech, Inc, Gyroscope, IVERIC bio, Kodiak Sciences Inc, Novartis Pharmaceuticals Corporation, Opthea, Oxurion NV, Recens Medical, Inc, and Regenxbio Inc.

    Dante Pieramici, MD, is a consultant for Adverum, Allegro Ophthalmics, LLC, Gemini Therapeutics, Genentech, Inc, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, and Regenxbio Inc; and is a contracted researcher for Adverum, Aerie Pharmaceuticals, Inc, Apellis Pharmaceuticals, Chengdu Kanghong Pharmaceutical Group Co Ltd, Gemini Therapeutics, Genentech, Inc, GrayBug, Inc, Ionis Pharmaceuticals, Inc, Kodiak Sciences Inc, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, Regenxbio Inc, Santen Inc, and Stealth BioTherapeutics Inc.

    Patient
    Dorene has no relevant commercial relationships to disclose.

    Peer Reviewer
    Gennady Landa, MD, has no relevant commercial relationships to disclose.

    Planners and Managers
    MedEdicus planners and managers have no relevant commercial relationships to disclose.

  • Target Audience

    This educational activity is intended for retina specialists and other ophthalmologists caring for patients with nAMD.

  • Learning Objectives

    After completing this activity, participants will be better able to:

    • Summarize the latest clinical trial data for approved and emerging treatments for neovascular age-related macular degeneration
    • Describe recent data on the relationship between retinal fluid and visual outcomes
    • Identify patients who would be good candidates for newer injection-based therapies, continuous treatment delivery, and treat-and-extend strategies for neovascular age-related macular degeneration
  • Accreditation and Credit Designation Statements

     MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    Credit Designation
    MedEdicus LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Instructions for Obtaining Credit
    To obtain AMA PRA Category 1 Credit™ for this activity, please view the webcast, consult referenced sources as necessary, and complete the post test and evaluation online. Upon passing with a score of 70% or higher, a certificate will be made available immediately.

    Off-Label Discussion
    This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.

  • Provider(s)/Educational Partner(s)

    This continuing medical education activity is provided by MedEdicus LLC.

    For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com. 

  • Commercial Support

    This continuing medical education activity is supported through an unrestricted educational grant from Genentech, Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or Genentech, Inc.

    This CME activity is copyrighted to MedEdicus LLC ©2020. All rights reserved. 231

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    The incidence of neovascular age-related macular degeneration (nAMD) is rising as a large segment of the US population ages. Despite recent advances in treatment, frequent injections and monitoring visits create a burden on patients that often leads to nonadherence, undertreatment, and suboptimal visual outcomes. In this unique educational activity, a patient with nAMD and 2 experts in retinal disease treatment discuss unmet needs in nAMD, strategies to reduce treatment burden using current therapies, and emerging strategies that harness either an implantable port or viral vectors to deliver anti–vascular endothelial growth factor therapy continuously to the vitreous. The desired results of this educational activity are for retina specialists and other ophthalmologists to use current evidence to support patient-centered treatment strategies for nAMD that minimize treatment burden while maximizing vision and quality of life outcomes.

  • Disclosure of Conflicts of Interest

    Disclosure Policy
    MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity.

    Faculty
    Arshad M. Khanani, MD, MA, is a consultant for Adverum, Allergan, Bausch & Lomb Incorporated, Chengdu Kanghong Pharmaceutical Group Co Ltd, D.O.R.C. Dutch Ophthalmic Research Center (International) B.V., EyePoint Pharmaceuticals, Gemini Therapeutics, Genentech, Inc, Gyroscope, Kodiak Sciences Inc, Novartis Pharmaceuticals Corporation, Opthea, Oxurion NV, Recens Medical, Inc, and Regenxbio Inc; is on the speakers bureau for Allergan, F. Hoffman-La Roche Ltd, Genentech, Inc, and Novartis Pharmaceuticals Corporation; and is a contracted researcher for Adverum, Allergan, Chengdu Kanghong Pharmaceutical Group Co Ltd, Gemini Therapeutics, Genentech, Inc, Gyroscope, IVERIC bio, Kodiak Sciences Inc, Novartis Pharmaceuticals Corporation, Opthea, Oxurion NV, Recens Medical, Inc, and Regenxbio Inc.

    Dante Pieramici, MD, is a consultant for Adverum, Allegro Ophthalmics, LLC, Gemini Therapeutics, Genentech, Inc, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, and Regenxbio Inc; and is a contracted researcher for Adverum, Aerie Pharmaceuticals, Inc, Apellis Pharmaceuticals, Chengdu Kanghong Pharmaceutical Group Co Ltd, Gemini Therapeutics, Genentech, Inc, GrayBug, Inc, Ionis Pharmaceuticals, Inc, Kodiak Sciences Inc, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, Regenxbio Inc, Santen Inc, and Stealth BioTherapeutics Inc.

    Patient
    Dorene has no relevant commercial relationships to disclose.

    Peer Reviewer
    Gennady Landa, MD, has no relevant commercial relationships to disclose.

    Planners and Managers
    MedEdicus planners and managers have no relevant commercial relationships to disclose.

  • Target Audience

    This educational activity is intended for retina specialists and other ophthalmologists caring for patients with nAMD.

  • Learning Objectives

    After completing this activity, participants will be better able to:

    • Summarize the latest clinical trial data for approved and emerging treatments for neovascular age-related macular degeneration
    • Describe recent data on the relationship between retinal fluid and visual outcomes
    • Identify patients who would be good candidates for newer injection-based therapies, continuous treatment delivery, and treat-and-extend strategies for neovascular age-related macular degeneration
  • Accreditation and Credit Designation Statements

     MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    Credit Designation
    MedEdicus LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Instructions for Obtaining Credit
    To obtain AMA PRA Category 1 Credit™ for this activity, please view the webcast, consult referenced sources as necessary, and complete the post test and evaluation online. Upon passing with a score of 70% or higher, a certificate will be made available immediately.

    Off-Label Discussion
    This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.

  • Provider(s)/Educational Partner(s)

    This continuing medical education activity is provided by MedEdicus LLC.

    For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com. 

  • Commercial Support

    This continuing medical education activity is supported through an unrestricted educational grant from Genentech, Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or Genentech, Inc.

    This CME activity is copyrighted to MedEdicus LLC ©2020. All rights reserved. 231

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 1/20/21